(Press-News.org) CHICAGO, JUNE 2, 2013 — The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Several patients experienced tumor shrinkage of more than 80 percent within 12 weeks of receiving the drugs, and the shrinkage was long lasting. Further, 40 percent of patients who received varying concurrent dosages had an objective response — meaning at least a 50 percent reduction in tumor size. Side effects from the drug combination were manageable and often reversible.
"We are very excited about the response rates these patients have experienced. This kind of deep and rapid tumor regression has never been seen in melanoma using immunotherapy, and suggests that these two drugs could be better used in combination than alone," said Jedd D. Wolchok, MD, PhD. Dr. Wolchok, a medical oncologist at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering, is lead author on The New England Journal of Medicine paper and also presented the findings at ASCO.
Dr. Wolchok and his team combined ipilimumab and nivolumab because promising results in preclinical testing suggested the drugs impact the immune system in a complementary way. By blocking the inhibitory marker CTLA-4, ipilimumab, which the FDA approved for advanced melanoma in 2011, activates the immune system, prompting T cells to start attacking the tumor. Blocking PD-1 further activates T cells in a different manner, allowing them to continue the attack.
"Previous studies had shown that ipilimumab alone could prolong overall survival in advanced melanoma patients, and nivolumab alone could produce durable tumor responses in melanoma and other cancers, so the combination of the two drugs was quite logical and well supported by preclinical and clinical trial data," he said.
However, Dr. Wolchok notes that not all patients respond to immunotherapy and determining why some patients do not is becoming an extremely important part of advancing this field.
Because of the strong Phase I findings, researchers will begin testing the combination this June as a therapy for patients newly diagnosed with advanced melanoma in a randomized Phase III trial led by Memorial Sloan-Kettering and taking place at more than 150 institutions worldwide.
###
The current research was supported by Bristol-Myers Squibb Inc and Ono Pharmaceutical Company Ltd.
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to http://www.mskcc.org.
Combination of drugs produces dramatic tumor responses in advanced melanoma patients
2013-06-02
ELSE PRESS RELEASES FROM THIS DATE:
Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
2013-06-02
Chicago, IL – The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of Neuro-Oncology.
Glioblastoma is both the most common and lethal form of brain ...
US oncologists report high career satisfaction, yet many suffer symptoms of burnout
2013-06-02
CHICAGO -- Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago.
"Oncology can be a tremendously rewarding area of medicine, but caring for patients with cancer is also demanding and stressful," says lead author Tait Shanafelt, M.D., a Mayo Clinic hematologist/oncologist. "Oncologists work long hours, supervise the administration of highly toxic ...
Abnormalities in HER2 gene found in wide variety of advanced cancers
2013-06-02
(CHICAGO) The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.
The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of these tumors might benefit from the three anti-HER2 therapies now in clinical use.
"No ...
Therapy that heats and destroys bone tumors eases patients' pain
2013-06-02
(CHICAGO) Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson's Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Mark Hurwitz, MD, Director of Thermal Oncology for the Department of Radiation Oncology at Thomas Jefferson University and Hospital reported that the treatment, ...
Targeted therapy sorafenib shows success in advanced differentiated thyroid cancer patients
2013-06-02
CHICAGO – The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting (Abstract #4).
If approved for use in thyroid cancer patients by the Food and Drug Administration, sorafenib (Nexavar), a kinase inhibitor that mediates tumor ...
UK doctors and nurses that are injured while treating unconscious patients cannot test them for HIV due to lack of legal protection, while in most of Europe such testing is permitted
2013-06-02
Doctors and nurses in the UK that are injured in the course of treating injured patients cannot currently test that patient for HIV without their consent. In emergency situations where the patient is unconscious, such consent cannot be given, putting healthcare staff at risk of subsequent legal action if they test the unconscious patient. In a session taking place at Euroanaesthesia (the annual congress of the European Society of Anaesthesiology [ESA]), senior UK anaesthetists will discuss the need for a change in the law to protect both patients and healthcare workers. ...
When to start (and not stop) resuscitation efforts
2013-06-02
One of the most difficult moments faced by anaesthetists and other healthcare staff is when to carry on attempts to resuscitate a person, and when those efforts should reasonably stop. This dilemma is the subject of a session at Euroanaesthesia, the annual congress of the European Society of Anaesthesiology (ESA).
In the first part of the session, Dr Jose Solsona, Director of the ICU Department and Chair of the Ethics Committee at Hospital del Mar, Barcelona, Spain, will outline scenarios in which it is advised not to begin cardiopulmonary resuscitation (CPR) efforts, ...
Empowering Family Caregivers Radio Show AddressesOnline Counseling for Caregivers
2013-06-02
Family caregivers face unique challenges and need innovative ways to manage those challenges. Online counseling is one option that many caregivers are considering, but without accurate information about how to choose an online counselor, these caregivers may not get what they need. Dr. Maheu said, "Caregivers often need help but make their own needs secondary to those of their loved ones. When choosing a professional for support, the professional be trained not only in how to help you with your situation, but must also be trained in how to protect you from hackers, ...
GammaTech Rugged Durabook TA10 Tablet Now Available for Industrial and Field Applications
2013-06-02
Ruggedness, Durability, and Enhanced Mobility Make the Durabook TA10 the Perfect Solution for Virtually Any Challenging or Remote Environment
GammaTech Computer Corp., a major international manufacturer and supplier of innovative notebook and tablet computers, announces that its latest Durabook high-end, rugged tablet, designed and engineered for demanding industrial and field applications, is now available. With its unique ruggedness, toughness, and durability, the Durabook model TA10 makes perfect sense for any worker whose job takes place in what can best be described ...
Start Gay Pride Month With Bedlam's Amazing Rendering of the "Trans-Dramedy": Walking The Dead by Keith Curran, Directed by Russell Boyle
2013-06-02
Just as relevant and revelatory today as when it first premiered in 1991, playwright Keith Curran's Walking the Dead finds folly amidst tragedy. The story begins at a funeral, where shock artist Maya Deboats has gathered friends and family to pay respects and build an artistic "installation memorial" to Maya's recently murdered lover Veronica. As the cast of outspoken eccentrics—including a bigoted mother, an alcoholic ex, and a failed documentary maker— share their memories of the deceased, the play flashes back to Veronica's life as a transgendered man named ...